Technology area: Biotechnology & Pharmaceuticals
14 pending office actions • 10 clients • 13 examiners • 11 art units • 0 of 14 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
BELL & ASSOCIATES operates in the Biotechnology & Pharmaceuticals technology area with 548 career applications. The firm has a resolved allowance rate of 76.54 percent. This is achieved with an average of 2.89 office actions per allowance.
Currently, the firm has 14 pending office actions. The 76.54 percent resolved allowance rate across 548 career applications establishes a track record for its clients. Practitioners can expect 2.89 office actions per allowance based on these historical metrics. The 14 pending office actions represent the current volume of work in this technology area. This data provides a view of the firm's prosecution history and current docket status.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (14%) |
| §102 only | 1 (7%) |
| §112 only | 4 (29%) |
| Double-patenting + other | 3 (21%) |
| Multi-statute (no §101) | 3 (21%) |
| No statute on record | 1 (7%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SEAMAN, D MARGARET M | 2 | 76.6% | +8.1% |
| SAEED, KAMAL A | 1 | 83.8% | +9.8% |
| SHIAO, REI TSANG | 1 | 79.9% | -33.5% |
| BAUER, BRIANNA LEE | 1 | 66.7% | +0.0% |
| SHAMEEM, GOLAM M | 1 | 86.7% | +15.9% |
| THOMAS, SOUMYA | 1 | 66.7% | -25.0% |
| CESARE, JOSEPH DAVID | 1 | — | — |
| MUMMERT, STEPHANIE KANE | 1 | 61.4% | +21.2% |
| VISHNYAKOVA, ELENA VLADIMIROVNA | 1 | 68.3% | +46.6% |
| BURKETT, DANIEL JOHN | 1 | 63.4% | +33.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18704068 | COMPOSITION FOR PREVENTING OR TREATING GRAVES' DISEASE COMPRISING COMPOUND CONTAINING AN IMIDAZOPYRIDINE STRUCTURE AS ACTIVE INGREDIENT | SAEED, KAMAL A | — |
| 18684802 | APPLICATION OF BENZISOQUINOLINE DIKETONE COMPOUND IN TREATMENT OF TUMOR | SHAMEEM, GOLAM M | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035429 | APPLICATION OF ISOQUINOLINE COMPOUND IN TUMOR TREATMENT | BURKETT, DANIEL JOHN | 53d |
| 18684789 | APPLICATION OF BENZANILIDE COMPOUND IN TUMOR TREATMENT | SEAMAN, D MARGARET M | — |
| 18685925 | APPLICATION OF HYDRAZIDE COMPOUND IN TUMOR TREATMENT | BAUER, BRIANNA LEE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035429 | APPLICATION OF ISOQUINOLINE COMPOUND IN TUMOR TREATMENT | BURKETT, DANIEL JOHN | 53d |
| 18684802 | APPLICATION OF BENZISOQUINOLINE DIKETONE COMPOUND IN TREATMENT OF TUMOR | SHAMEEM, GOLAM M | — |
| 18554150 | SYSTEMS, METHODS, AND COMPOSITIONS FOR DETECTING EPIGENETIC MODIFICATIONS OF NUCLEIC ACIDS | MUMMERT, STEPHANIE KANE | — |
| 18268236 | BENZENE RING COMPOUND AND USE THEREOF | VISHNYAKOVA, ELENA VLADIMIROVNA | — |
| Art Unit | Apps |
|---|---|
| 1625 | 2 |
| 1626 | 2 |
| 1691 | 2 |
| 1621 | 1 |
| 2664 | 1 |
| 1618 | 1 |
| 1681 | 1 |
| 1624 | 1 |
| 1658 | 1 |
| 1638 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18942833 | HALOGENATED BENZYLIDINE DERIVATIVES | Renovel Innovations, Inc. | SEAMAN, D MARGARET M | 1625 | §102DP | Non-Final OA | — | Pending | Nov 11, 2024 |
| 18704068 | COMPOSITION FOR PREVENTING OR TREATING GRAVES' DISEASE COMPRISING COMPOUND CONTAINING AN IMIDAZOPYRIDINE STRUCTURE AS ACTIVE INGREDIENT | Esgelbio Inc. | SAEED, KAMAL A | 1626 | §112 | Non-Final OA | — | Pending | Apr 24, 2024 |
| 18686461 | APPLICATION OF TETRACYCLINE COMPOUND IN TREATMENT OF TUMOR | Nanjing Shijiang Medicine Technology Co., Ltd. | SHIAO, REI TSANG | 1691 | §103 | Final Rejection | — | Pending | Apr 22, 2024 |
| 18684789 | APPLICATION OF BENZANILIDE COMPOUND IN TUMOR TREATMENT | Nanjing Shijiang Medicine Technology Co., Ltd. | SEAMAN, D MARGARET M | 1625 | §102§112 | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18685925 | APPLICATION OF HYDRAZIDE COMPOUND IN TUMOR TREATMENT | Nanjing Shijiang Medicine Technology Co., Ltd. | BAUER, BRIANNA LEE | 1626 | §102§103§112 | Non-Final OA | — | Pending | Feb 23, 2024 |
| 18684802 | APPLICATION OF BENZISOQUINOLINE DIKETONE COMPOUND IN TREATMENT OF TUMOR | Nanjing Shijiang Medicine Technology Co., Ltd. | SHAMEEM, GOLAM M | 1621 | §112 | Non-Final OA | — | Pending | Feb 19, 2024 |
| 18437291 | A System for Tracking, Locating and Calculating the Position of a First Moving Object in Relation to a Second Object | Hall, Matthew | THOMAS, SOUMYA | 2664 | §103Other | Final Rejection | — | Pending | Feb 09, 2024 |
| 18562298 | ANTI-PD-1 POLYPEPTIDES AND THEIR USE | Beijing Kanova Biopharmaceutical Co., Ltd. | CESARE, JOSEPH DAVID | 1618 | §112 | Non-Final OA | — | Pending | Nov 18, 2023 |
| 18554150 | SYSTEMS, METHODS, AND COMPOSITIONS FOR DETECTING EPIGENETIC MODIFICATIONS OF NUCLEIC ACIDS | Kalim Mir | MUMMERT, STEPHANIE KANE | 1681 | §102 | Non-Final OA | — | Pending | Oct 05, 2023 |
| 18268236 | BENZENE RING COMPOUND AND USE THEREOF | Nanjing Shijiang Medicine Technology Co., Ltd. | VISHNYAKOVA, ELENA VLADIMIROVNA | 1691 | §103DP | Final Rejection | — | Pending | Jun 18, 2023 |
| 18035429 | APPLICATION OF ISOQUINOLINE COMPOUND IN TUMOR TREATMENT | Tongji University | BURKETT, DANIEL JOHN | 1624 | §102§112 | Non-Final OA | 53d | Pending | May 04, 2023 |
| 17641539 | APPLICATION OF NON-IGF1R-BINDING SUBSTANCE IN PREVENTION AND/OR TREATMENT OF INFLAMMATORY DISEASES | Shanghai Institute Of Nutrition And Health, Chinese Academy Of Sciences | STEELE, AMBER D | 1658 | §102§103§112DP | Non-Final OA | — | Pending | Aug 23, 2022 |
| 17292296 | USE OF ECM1 GENE-KNOCKOUT MOUSE IN SCREENING OF ANTI-HEPATIC FIBROSIS DRUG | Center For Excellence In Molecular Cell Science, Chinese Academy Of Sciences | ROGERS, ERIC JASON | 1638 | §112 | Non-Final OA | 8d | Pending | Sep 15, 2021 |
| 17050168 | REPEAT-MEDIATED PLANT SITE-SPECIFIC RECOMBINATION METHOD | Cas Center For Excellence In Molecular Plant Sciences | BYRNES, DAVID R | 1662 | — | Final Rejection | 1d overdue | Pending | Oct 23, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial76.5% of resolved applications prosecuted by Bell & Associates were allowed, across 548 applications in USPTO records.
2.89 office actions per allowed application on average.
14 pending office actions as of October 2026, for 10 clients, before 13 examiners in 11 art units.
